Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ)
CNY 37.97
(-4.24%)
CNY 37.97
(-4.24%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.05 Billion CNY | -15.18% |
| 2022 | 1.04 Billion CNY | 2.11% |
| 2021 | 914.63 Million CNY | 80.05% |
| 2020 | 377.1 Million CNY | -46.28% |
| 2019 | 1.09 Billion CNY | -41.19% |
| 2018 | 1.81 Billion CNY | 2.96% |
| 2017 | 1.85 Billion CNY | 3.33% |
| 2016 | 1.77 Billion CNY | 14.77% |
| 2015 | 1.52 Billion CNY | 24.09% |
| 2014 | 1.23 Billion CNY | 21.92% |
| 2013 | 1.01 Billion CNY | 33.05% |
| 2012 | 757.42 Million CNY | 55.63% |
| 2011 | 485.16 Million CNY | 11.0% |
| 2010 | 435.39 Million CNY | 65.66% |
| 2009 | 263.77 Million CNY | 94.5% |
| 2008 | 136.72 Million CNY | 63.37% |
| 2007 | 84.2 Million CNY | 97.92% |
| 2006 | 41.8 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 181.77 Million CNY | -33.38% |
| 2024 Q2 | 229.88 Million CNY | -19.87% |
| 2024 Q1 | 238.33 Million CNY | 72.53% |
| 2023 Q4 | 202.36 Million CNY | 22.07% |
| 2023 Q2 | 164.73 Million CNY | -32.31% |
| 2023 Q1 | 243.36 Million CNY | 57.04% |
| 2023 Q3 | 165.78 Million CNY | 0.63% |
| 2023 FY | - CNY | -15.18% |
| 2022 Q1 | 268.77 Million CNY | 3.58% |
| 2022 Q4 | 154.96 Million CNY | -32.66% |
| 2022 Q3 | 230.11 Million CNY | 92.64% |
| 2022 FY | - CNY | 2.11% |
| 2022 Q2 | 119.45 Million CNY | -55.56% |
| 2021 Q2 | 101.57 Million CNY | -46.57% |
| 2021 Q1 | 190.11 Million CNY | 541.82% |
| 2021 Q3 | 215.37 Million CNY | 112.04% |
| 2021 Q4 | 259.49 Million CNY | 20.48% |
| 2021 FY | - CNY | 80.05% |
| 2020 Q3 | 87.97 Million CNY | 89.72% |
| 2020 Q4 | 29.62 Million CNY | -66.33% |
| 2020 FY | - CNY | -46.28% |
| 2020 Q1 | 184.74 Million CNY | 1970.72% |
| 2020 Q2 | 46.37 Million CNY | -74.9% |
| 2019 Q2 | 375.33 Million CNY | -2.06% |
| 2019 FY | - CNY | -41.19% |
| 2019 Q1 | 383.21 Million CNY | 6.6% |
| 2019 Q3 | 110.19 Million CNY | -70.64% |
| 2019 Q4 | 8.92 Million CNY | -91.9% |
| 2018 Q2 | 438.24 Million CNY | -9.81% |
| 2018 Q4 | 359.49 Million CNY | -14.92% |
| 2018 FY | - CNY | 2.96% |
| 2018 Q1 | 485.92 Million CNY | 9.35% |
| 2018 Q3 | 422.56 Million CNY | -3.58% |
| 2017 Q3 | 427.81 Million CNY | 6.98% |
| 2017 Q2 | 399.89 Million CNY | -7.07% |
| 2017 FY | - CNY | 3.33% |
| 2017 Q1 | 430.32 Million CNY | -4.63% |
| 2017 Q4 | 444.36 Million CNY | 3.87% |
| 2016 Q2 | 399.89 Million CNY | -2.79% |
| 2016 FY | - CNY | 14.77% |
| 2016 Q4 | 451.23 Million CNY | 14.49% |
| 2016 Q1 | 411.39 Million CNY | 7.67% |
| 2016 Q3 | 394.11 Million CNY | -1.45% |
| 2015 Q2 | 363.34 Million CNY | -0.44% |
| 2015 FY | - CNY | 24.09% |
| 2015 Q4 | 382.09 Million CNY | 7.44% |
| 2015 Q3 | 355.62 Million CNY | -2.12% |
| 2015 Q1 | 364.94 Million CNY | 10.98% |
| 2014 FY | - CNY | 21.92% |
| 2014 Q4 | 328.84 Million CNY | 14.25% |
| 2014 Q1 | 290.95 Million CNY | 10.69% |
| 2014 Q3 | 287.83 Million CNY | 6.06% |
| 2014 Q2 | 271.38 Million CNY | -6.73% |
| 2013 Q2 | 226.34 Million CNY | -5.57% |
| 2013 FY | - CNY | 33.05% |
| 2013 Q4 | 262.86 Million CNY | 11.28% |
| 2013 Q3 | 236.22 Million CNY | 4.36% |
| 2013 Q1 | 239.69 Million CNY | 6.51% |
| 2012 Q1 | 148.96 Million CNY | 9.85% |
| 2012 FY | - CNY | 55.63% |
| 2012 Q2 | 137.51 Million CNY | -7.68% |
| 2012 Q3 | 212.86 Million CNY | 54.79% |
| 2012 Q4 | 225.03 Million CNY | 5.71% |
| 2011 Q2 | 102.65 Million CNY | -16.68% |
| 2011 Q1 | 123.19 Million CNY | 2.12% |
| 2011 FY | - CNY | 11.0% |
| 2011 Q4 | 135.61 Million CNY | 36.98% |
| 2011 Q3 | 98.99 Million CNY | -3.56% |
| 2010 Q1 | 105.77 Million CNY | 21.82% |
| 2010 Q2 | 106.86 Million CNY | 1.03% |
| 2010 Q3 | 90.14 Million CNY | -15.64% |
| 2010 Q4 | 120.64 Million CNY | 33.83% |
| 2010 FY | - CNY | 65.66% |
| 2009 Q1 | 47.37 Million CNY | 49.49% |
| 2009 Q2 | 60.08 Million CNY | 26.81% |
| 2009 Q3 | 58.86 Million CNY | -2.02% |
| 2009 FY | - CNY | 94.5% |
| 2009 Q4 | 86.82 Million CNY | 47.5% |
| 2008 Q3 | 38.41 Million CNY | 0.0% |
| 2008 FY | - CNY | 63.37% |
| 2008 Q4 | 31.69 Million CNY | -17.5% |
| 2007 FY | - CNY | 97.92% |
| 2006 FY | - CNY | 0.0% |